While neovascular forms of AMD can now be effectively treated by repetitive injections of vascular endothelial growth factor (VEGF) inhibitors for preventing further loss of vision, no therapy is available for the dry late manifestation (geographic atrophy) [1]. Here, VEGFA is linked to atrophic macular degeneration.